$40,000 of CLOVER HEALTH lobbying was just disclosed, from Q1 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Medicare Advantage Issues"
You can find more data on corporate lobbying on Quiver Quantitative.
CLOV Insider Trading Activity
CLOV insiders have traded $CLOV stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $CLOV stock by insiders over the last 6 months:
- BRADY PATRICK PRIEST (CEO of Clover Care Services) has made 0 purchases and 2 sales selling 273,039 shares for an estimated $724,847.
- JAMIE L. REYNOSO (CEO, Medicare Advantage) has made 0 purchases and 4 sales selling 17,445 shares for an estimated $41,142.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
CLOV Hedge Fund Activity
We have seen 94 institutional investors add shares of CLOV stock to their portfolio, and 105 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- DIVISADERO STREET CAPITAL MANAGEMENT, LP removed 2,768,088 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $6,505,006
- HRT FINANCIAL LP added 1,667,691 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,935,136
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 1,426,696 shares (-61.4%) from their portfolio in Q1 2026, for an estimated $2,510,984
- GMT CAPITAL CORP added 1,305,200 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,297,152
- MILLENNIUM MANAGEMENT LLC added 1,164,968 shares (+inf%) to their portfolio in Q1 2026, for an estimated $2,050,343
- RENAISSANCE TECHNOLOGIES LLC removed 1,089,600 shares (-24.3%) from their portfolio in Q1 2026, for an estimated $1,917,696
- JUPITER ASSET MANAGEMENT LTD removed 850,884 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $1,999,577
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
CLOV Price Targets
Multiple analysts have issued price targets for $CLOV recently. We have seen 2 analysts offer price targets for $CLOV in the last 6 months, with a median target of $2.85.
Here are some recent targets:
- Richard Close from Canaccord Genuity set a target price of $3.2 on 03/20/2026
- Whit Mayo from Leerink Partners set a target price of $2.5 on 03/05/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
